Source: Annual Congress 2003 - New aspects of community acquired pneumonia
Disease area: Airway diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
G. Piatti, U. Ambrosetti, M. Dal Sasso, P. Braga, C. Gambardella, L. Allegra (Milan, Italy). Effects of salmeterol on the ciliary beat in patients with community-acquired pneumonia. Eur Respir J 2003; 22: Suppl. 45, 136

Member's Comments

No comment yet.

Related content which might interest you: Comparison of costs of community-acquired pneumonia (CAP) treatment at patients with and without bronchial obstruction Source: Annual Congress 2011 - COPD management Year: 2011 Heliox-therapy of patients with execerbation of COPD and community-acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 106s Year: 2006 Effects of salmeterol on ciliary beat and mucus rheology in COPD patients Source: Eur Respir J 2003; 22: Suppl. 45, 78s Year: 2003 Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients Source: Eur Respir J 2015; 45: 463-472 Year: 2015 Efficacy of corticosteroids in hospital treated community-acquired pneumonia Source: Annual Congress 2012 - Clinical management of lung diseases: from bronchi to pleura Year: 2012 Etiology pathogens structure in community-acquired pneumonias and COPD exacerbations Source: Annual Congress 2011 - Role of infection in exacerbations of COPD Year: 2011 COPD: what is the frequency and impact of community-acquired pneumonia? Source: Annual Congress 2008 - Community-acquired pneumonia and COPD: what do we know? Year: 2008 Analysis of therapy of community-acquired pneumonia (CAP) at the COPD patients Source: Annual Congress 2011 - COPD management Year: 2011 Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia Source: Eur Respir J 2011; 37: 36-41 Year: 2011 Penetration of moxifloxacin in bronchial secretions in hospitalized patients with acute exacerbation of COPD Source: Annual Congress 2013 –Antibiotics, resistance and vaccines Year: 2013 Low-dose corticosteroids during severe community-acquired pneumonia: end of the story Source: Eur Respir J 2015; 45: 305-307 Year: 2015 Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia Source: Eur Respir J 2010; 36: 128-134 Year: 2010 Peculiarities of community-acquired pneumonia in tobacco-smoking patients Source: Annual Congress 2009 - Tobacco: from smoke to disease Year: 2009 Efficacy and safety of levofloxacin treatment of community-acquired pneumonia in hospitalized patients Source: Eur Respir J 2005; 26: Suppl. 49, 637s Year: 2005 Delirium induced by clarithromycin in a patient with community-acquired pneumonia Source: Eur Respir J 2006; 28: 671-672 Year: 2006 Are corticosteroids useful in community-acquired pneumonia? Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia Year: 2006 Antipyretic effect of dexamethasone in community-acquired pneumonia Source: Eur Respir J 2015; 46: 570-573 Year: 2015 Enhanced neutrophil response in patients with chronic bronchitis and community-acquired pneumonia (CAP) Source: Eur Respir J 2002; 20: Suppl. 38, 418s Year: 2002 Cost of treatment failure in community-acquired pneumonia Source: Eur Respir J 2007; 30: Suppl. 51, 195s Year: 2007 Comparing pneumonia incidence in COPD patients treated with or without inhaled corticosteroid Source: Virtual Congress 2021 – Inhaled treatments for COPD: real-world data Year: 2021